Hypothalamic but Not Pituitary or Ovarian Defects Underlie the Reproductive Abnormalities in Axl/Tyro3 Null Mice
Overview
Endocrinology
Molecular Biology
Authors
Affiliations
AXL and TYRO3, members of the TYRO3, AXL and MER (TAM) family of tyrosine kinase receptors, modulate GnRH neuronal cell migration, survival and gene expression. Axl/Tyro3 null mice exhibit a selective loss of GnRH neurons, delayed sexual maturation and irregular estrous cycles. Here we determined whether the defects were due to direct ovarian defects, altered pituitary sensitivity to GnRH and/or an impaired LH surge mechanism. Ovarian histology and markers of folliculogenesis and atresia as well as corpora luteal development and ovarian response to superovulation were not impaired. Axl/Tryo3 null mice exhibited a robust LH response to exogenous GnRH, suggesting no altered pituitary sensitivity. Ovariectomized Axl/Tyro3 null mice, however, demonstrated an impaired ability to mount a steroid-induced LH surge. Loss of GnRH neurons in Axl/Tyro3 null mice impairs the sex hormone-induced gonadotropin surge resulting in estrous cycle abnormalities confirming that TAM family members contribute to normal female reproductive function.
AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling.
Mohammadzadeh P, Roueinfar M, Amberg G Cell Commun Signal. 2023; 21(1):284.
PMID: 37828510 PMC: 10568877. DOI: 10.1186/s12964-023-01313-y.
AXL/Gas6 signaling mechanisms in the hypothalamic-pituitary-gonadal axis.
Mohammadzadeh P, Amberg G Front Endocrinol (Lausanne). 2023; 14:1212104.
PMID: 37396176 PMC: 10310921. DOI: 10.3389/fendo.2023.1212104.
TAM Signaling in the Nervous System.
Burstyn-Cohen T, Hochberg A Brain Plast. 2021; 7(1):33-46.
PMID: 34631419 PMC: 8461745. DOI: 10.3233/BPL-210125.
Al Kafri N, Hafizi S Cancers (Basel). 2019; 11(12).
PMID: 31766614 PMC: 6966665. DOI: 10.3390/cancers11121843.
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart S, Vasileiadi E, Wang X, DeRyckere D, Graham D Cancers (Basel). 2018; 10(12).
PMID: 30501104 PMC: 6316664. DOI: 10.3390/cancers10120474.